Year of investment: 2009
TiGenix is a late-stage regenerative medicine company active in tissue engineering (cartilage repair) and allogeneic cell therapy. It has a marketing agreement with Sobi AB for its ChrondroCelect product in Europe. Its cell therapy products are in advanced stages of clinical trials. TiGenix NV is listed at Euronext Brussels.
Year of investment: 2007
PharmaCell is world leader in cell-culturing services using its GMP-certified manufacturing facilities in Maastricht and Geleen. Its customers include the world leaders in commercial cell therapy products. Pharmacell has access to an extensive network which gives it the capability to provide support and/or partnership to R&D companies to bring new products from the lab into the clinic.